The administration of EN4 (50 mg/kg; intraperitoneal injection; daily; for 3 weeks) led to a significant reduction in tumor growth in 231MFP breast tumor xenograft mice^[1].

EN4 treatment at concentrations ranging from 1 to 50 μM for 72 hours markedly reduces proliferation of 231MFP breast cancer cells in a dose-dependent manner, achieving over 90% inhibition of proliferation at 50 μM^[1].

EN4 treatment at a concentration of 50 μM for 60 hours significantly reduces the protein levels of representative MYC-regulated target genes, such as CDK2 and CDC25A. Additionally, EN4 treatment markedly decreases MYC levels^[1].

EN4 demonstrates potent inhibition of both MYC/MAX binding to its DNA consensus sequence in vitro and MYC transcriptional activity in cells. It inhibits MYC/MAX binding to the E-box response element DNA consensus sequence in a dose-dependent manner, with an IC50 value of 6.7 μM. Additionally, EN4 inhibits MYC luciferase reporter activity in a dose-dependent manner, with an IC50 value of 2.8 μM^[1].

EN4 treatment (50 μM; for 2 hours) resulted in a significant reduction in the thermal stability of MYC in 231MFP breast cancer cells^[1].